Local 12: Study: Targeted drug therapy slows progression of certain brain tumors
Drug could reduce the need for chemotherapy, radiation and surgery, UC expert says
New research out of the University of Cincinnati shows a targeted drug therapy had positive results in delaying the progression of a specific form of glioma, which is a slow-growing brain tumor.
UC Cancer Center brain tumor specialists said it appears to be an option for treatment and would delay radiation and chemotherapy. Local 12 interviewed Rekha Chaudhary, MD, of the Department of Internal Medicine at the UC College of Medicine who said this drug is given after surgery to remove this kind of tumor and appears to be a powerful player in reducing new growth.
Rekha Chaudhary, MD, of the Department of Internal Medicine at the UC College of Medicine/Photo/Colleen Kelley/UC Marketing + Brand
"This new drug Vorasidenib is an IDH1, IDH2 inhibitor. And what it does, it actually inhibits these receptors that are found, or proteins that are found on the tumors,” Chaudhary said.
Researchers studied 331 people with this disease and compared the study drug to a placebo. Those given the targeted therapy did not have disease progression for more than 27.7 months. For those in the placebo group, it was only 11.1 months.
"Whether this is going to pan out to be a survival benefit in the long run, we don't know. But imagine being 30 years old and not having to go through chemo, radiation, further surgery and just be on this drug for almost three years now, and hopefully longer, is a great benefit to these patients, where we've never had a victory before,” Chaudhary told Local 12.
This targeted treatment was so effective that the patients in the original placebo group whose cancer progressed during the study were switched to the drug. It gives promising new hope.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.